Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial
Sponsor: Bayside Health
Summary
Prophylactic TxA administration in patients undergoing major gastrointestinal surgery reduces the incidence of delirium after surgery when compared with placebo. The unifying hypothesis is that systemic and neuro-inflammation lead to neuronal injury and resultant postoperative delirium.
Official title: Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial (a Substudy of the TRIGS Trial)
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
826
Start Date
2022-11-01
Completion Date
2026-08-31
Last Updated
2025-12-31
Healthy Volunteers
No
Conditions
Interventions
Tranexamic Acid 100Mg/ml Inj Vial 10ml
Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
Placebo
Normal saline
Locations (1)
Alfred Health
Melbourne, Victoria, Australia